Richard Rosenquist Brandell appointed Wallenberg Clinical Scholar

Published: 2017-03-23


Richard Rosenquist Brandell, Uppsala University/SciLifeLab, Platform Director for Diagnostics Development and Head of Facility for Clinical Genomics Uppsala, has been appointed Wallenberg Clinical Scholar by The Kut and Alice Wallenberg foundation.

Richard Rosenquist Brandell

Richard Rosenquist Brandell

As a Wallenberg Clinical Scholar, Richard Rosenquist Brandell will use the infrastructure for large-scale investigation of cells and their genetic material at SciLifeLab to systematically study blood cancer cells from different groups of patients and stages of the disease. The goal is to understand why some cancer cells more or less lie dormant, while others grow aggressively and why do some cancer cells die from chemotherapy, while others spread unhindered despite treatment. An important aim of the project is to provide better prognoses for those affected.

About the Wallenberg Clinical Scholars program
The program supports and encourages some of the most successful clinical researchers at Swedish universities and university hospitals. During the program period, 2015-2025, twenty-five grants will be awarded to Sweden’s foremost clinical researchers. This amounts to SEK 600 million; each researcher receives SEK 15 million for a five-year period, with the potential for a five-year extension. Wallenberg Clinical Scholars is part of the SEK 2.5 billion that the Knut and Alice Wallenberg Foundation is investing to boost medical research and the life sciences over a ten-year period. Universities with medical faculties are invited to nominate researchers for these research grants. The Royal Swedish Academy of Sciences is responsible for the scientific evaluation.